^
    5ms
    AK109-201: A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Akeso | N=87 --> 138 | Trial completion date: Jan 2024 --> Jan 2027 | Trial primary completion date: Jul 2023 --> Oct 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    paclitaxel • Kaitanni (cadonilimab) • pulocimab (AK109)
    5ms
    A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=506, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    paclitaxel • Kaitanni (cadonilimab) • pulocimab (AK109)
    7ms
    A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=198, Recruiting, Akeso | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Feb 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Kaitanni (cadonilimab) • pulocimab (AK109)
    8ms
    A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=506, Not yet recruiting, Akeso
    New P3 trial
    |
    paclitaxel • Kaitanni (cadonilimab) • pulocimab (AK109)
    2years
    A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=198, Recruiting, Akeso | Trial completion date: Oct 2023 --> Mar 2024 | Trial primary completion date: Aug 2022 --> Feb 2023
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Kaitanni (cadonilimab) • pulocimab (AK109)
    almost3years
    A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=198, Recruiting, Akeso
    Clinical • New P1/2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Kaitanni (cadonilimab) • pulocimab (AK109)